What is API Holdings Limited?

API Holdings Limited is the holding company of the PharmEasy digital health and online pharmacy platform. Incorporated in 2019 in Mumbai, it holds operating subsidiaries including the PharmEasy pharmacy aggregator platform and a majority stake in listed Thyrocare Technologies Limited (diagnostics).

Who are the founders of PharmEasy / API Holdings?

PharmEasy was co-founded by Siddharth Shah (CEO), Dhaval Shah, Dharmil Sheth, Harsh Parekh, and Hardik Dedhia. The founding team incorporated API Holdings Limited in 2019 as the group holding entity.

What happened to PharmEasy's IPO?

API Holdings filed a Draft Red Herring Prospectus (DRHP) with SEBI in 2021 for an IPO. However, the IPO was subsequently put on hold and formally withdrawn in 2022 due to adverse market conditions, rising interest rates, and the company's significant ongoing losses. A re-IPO remains a medium-term aspiration contingent on demonstrating profitability.

Is API Holdings Limited listed on any stock exchange?

No. API Holdings Limited is an unlisted public company. Its subsidiary Thyrocare Technologies Limited is separately listed on NSE and BSE (ticker: THYROCARE). API Holdings' own shares trade only in the unlisted/grey market.

How do I buy PharmEasy (API Holdings) unlisted shares here?

Raise an enquiry on any company with the quantity you want. Our desk sources the shares and comes back with a firm price and allocation. You accept the allocation, transfer the funds to the desk's published bank account, and once we verify payment the shares are transferred into your demat.

Who am I actually transacting with?

You transact with the desk, not with an anonymous counterparty. When you buy, you buy from the desk; when you sell, you sell to the desk. Shares always route through the desk's own demat account, so there's one accountable party for the whole trade.

How do I pay, and is there a payment gateway?

Payment is by direct bank transfer to Prospire Network Private Limited's published account (CIN U82300UP2025PTC233622), shown to you in-app at the payment step. There is no card gateway and no escrow. Never pay to a personal account or to any account shared over phone, WhatsApp or email — even if the person claims to be from our team.

How long does settlement take?

After you accept an allocation, you have a short window to pay (typically 2 days). Once payment is verified, shares are usually credited to your demat within 2–3 business days, subject to depository timelines and any company-level restrictions. Timeframes are typical, not guaranteed.

There are no separate platform fee lines and no GST on the transfer — the desk's margin is built into the buy/sell price you're quoted. The only statutory add-on on a purchase is stamp duty on the consideration, shown transparently in your cost breakdown.

Is there a minimum ticket size for PharmEasy (API Holdings)?

Minimums vary by company and depend on the lot the desk can source. Raise an enquiry and the desk will confirm the available quantity and the minimum for that name.

What KYC do I need, and do I need a demat account?

You'll share your demat details when you enquire so we can settle directly. Full KYC — PAN and a client-master / demat statement — is required before the transfer step, when shares actually change hands. Yes, you need an active demat account to hold unlisted shares.

Are there lock-ins on unlisted or pre-IPO shares?

Some shares carry statutory or company-imposed lock-ins — for example, a post-listing lock-in on pre-IPO stock — and transfers can be subject to the company's articles or approvals. Where a lock-in applies, we'll flag it before you commit.

How do I sell PharmEasy (API Holdings) shares I already hold?

Raise a sell enquiry with the company, quantity and your target price. The desk confirms a buying price, you transfer your shares into the desk's demat, and once the credit is verified we pay you out by bank transfer to your registered account. The desk never pays out before your shares are received.

Unlisted shares are illiquid, may be hard or impossible to sell, and are not covered by exchange settlement guarantees or investor-protection funds. Pricing is indicative, not live. Read the full Risk Disclosure before you enquire, and invest only what you can afford to lock away.

PharmEasy (API Holdings) Unlisted Share Price | Buy PharmEasy (API Holdings) Pre-IPO Shares — wisefolio

Unlisted shares are illiquid and carry higher risk than listed securities. Prices are indicative, not live. Read the risk disclosure.

Talk to us

PharmEasy (API Holdings) Unlisted Share Price | Buy PharmEasy (API Holdings) Pre-IPO Shares — wisefolio | wisefolio

Investment Thesis

API Holdings (PharmEasy) is India's leading digital pharmacy holding company with a strategically important position in online pharmacy and diagnostics (via Thyrocare). However, the company has experienced one of the most dramatic valuation collapses in India's startup ecosystem — from a USD 5.6 billion unicorn in 2021 to a distressed down-round in 2023. The withdrawn IPO, persistent losses, rights issue dilution, and Thyrocare acquisition controversy collectively create a challenging investment narrative. Only investors with very high risk tolerance and a long-term time horizon should consider exposure at the current price of INR 5.7.

Pros

Parent company of PharmEasy, India's largest online pharmacy platform by GMV with 60,000+ pharmacy partners onboarded
Controls Thyrocare Technologies Limited (listed on NSE/BSE: THYROCARE), providing a listed subsidiary anchor with stable diagnostics revenue
Integrated digital health ecosystem spanning online pharmacy, diagnostics booking, teleconsultation, and chronic disease management
Strong brand recognition in Indian digital health driven by PharmEasy's consumer platform
Significant prescription and health data moat enabling personalised healthcare offerings

Cons

Severe financial distress: valuation collapsed approximately 90% from USD 5.6 billion peak in 2021 to ~USD 300-400 million range in 2023 rights issue
Persistent and large net losses with continued dependency on external fundraising rounds
Withdrew IPO application in 2022 due to adverse market conditions after filing DRHP with SEBI in 2021
Acquired Thyrocare Technologies in 2021 at a significant premium of ~INR 4,546 crore and subsequently faced pressure to monetise the stake to reduce holding company debt
Rights issue in 2023 at a deep discount significantly diluted existing shareholders
Intense competition from Tata 1mg, Apollo Pharmacy Online, Flipkart Health+, and Amazon Pharmacy

Business Segments

Online Pharmacy (PharmEasy)

Aggregates 60,000+ pharmacy partners; customers order prescription and OTC medicines via app and website for home delivery. Largest segment by GMV.

Diagnostics (Thyrocare)

Thyrocare Technologies Limited (listed subsidiary) provides diagnostic testing services across India with a hub-and-spoke laboratory network. API Holdings holds a majority controlling stake.

Teleconsultation & Digital Health

Connects patients with doctors online for consultations; integrated with chronic disease management programs and medication delivery workflows.

Revenue Model

API Holdings generates revenue through commissions from pharmacy partners on medicine orders placed via the PharmEasy platform, consolidated revenue from majority-owned Thyrocare Technologies (diagnostic testing services), subscription fees for chronic disease management plans, and fees from teleconsultation services. A B2B arm also supplies medicines to hospital pharmacies at scale.

Detailed Analysis

Growth outlookExpansion plans, industry tailwinds & headwinds12

Growth Plans

Regulatory clarity on online pharmacy licensing enabling a more scalable and compliant operating model in India

Thyrocare growth driving improvement in consolidated group profitability metrics

Potential re-filing of IPO once financial metrics stabilise and market conditions improve

Market consolidation in digital pharmacy as weaker, underfunded players exit the sector

Industry Tailwinds

Recent Developments

Down-round rights issue completed

API Holdings raised emergency capital through a rights issue at an implied valuation of approximately USD 300-400 million — representing a roughly 90% decline from its 2021 peak valuation of USD 5.6 billion. The round significantly diluted existing shareholders and underscored the depth of the company's financial challenges.

2023-03

Thyrocare stake monetisation explored

API Holdings explored partial monetisation of its controlling stake in listed Thyrocare Technologies Limited to generate liquidity and reduce holding company debt, raising strategic questions about the long-term ownership of the diagnostics asset.

2023-06

Operational restructuring and path to profitability

PharmEasy undertook workforce rationalisation, reduced warehouse footprint, and narrowed geographic focus to higher-margin markets as part of efforts to reduce cash burn and demonstrate a viable path to profitability ahead of any potential re-IPO attempt.

Comparable Companies

CompanyTypeTickerMkt Cap

Thyrocare Technologies LimitedListedTHYROCARE~₹4,000-5,000 Cr

Tata 1mg (Tata Health)ListedUnlisted (Tata Digital subsidiary)~USD 1.5 billion (last implied valuation)

Apollo Hospitals Enterprise LimitedListedAPOLLOHOSP~₹90,000 Cr

Thyrocare Technologies LimitedListed

THYROCARE · ~₹4,000-5,000 Cr

Frequently Asked Questions

API Holdings acquired a majority stake in listed Thyrocare Technologies Limited in 2021 at approximately INR 1,300 per share (~INR 4,546 crore total), which was considered a premium acquisition. Subsequently, amid its own financial distress, API Holdings faced pressure to monetise the Thyrocare stake to reduce holding company debt, raising concerns about the strategic rationale and execution of the acquisition.

About PharmEasy (API Holdings)

API Holdings Limited, the parent entity behind the PharmEasy brand, is India's largest integrated digital healthcare platform by Gross Merchandise Value (GMV). Incorporated on 31 March 2019, the company has transformed from an online pharmacy startup into a comprehensive digital health ecosystem encompassing medicine delivery, diagnostics, teleconsultation, and hospital management. Headquartered at 1st Floor, E-Shape Building, Ashok Silk Mills Compound, Ghatkopar (West), Mumbai, API Holdings owns and operates a portfolio of healthcare brands including PharmEasy (online pharmacy), Thyrocare (diagnostics — listed BSE: THYROCARE), Docon (hospital management software), Aknamed (hospital supply chain), and Retailio (pharma distribution). The company was founded in 2015 by Dharmil Sheth, Dhaval Shah, and Siddharth Shah, initially as a Mumbai-based medicine delivery app. It rapidly scaled to become India's largest digital health platform through aggressive organic growth and strategic acquisitions, including the landmark acquisition of Thyrocare Technologies Limited — a listed diagnostics company — in 2021 for approximately ₹4,546 Crore, marking one of India's largest health tech acquisitions. API Holdings attempted an IPO in 2021, filing its DRHP, but withdrew it citing adverse market conditions. The company subsequently underwent a significant restructuring phase, reducing its valuation from peak estimates of $5.4 billion to more realistic levels. By FY2025, revenues had stabilized around ₹6,000 Crore, with losses narrowing sharply and operating cash flows nearing breakeven. Despite its fundraising and profitability challenges, API Holdings represents India's most ambitious digital healthcare infrastructure play. The company's B2C pharmacy platform PharmEasy serves millions of customers, while its B2B platforms (Aknamed, Retailio) digitize hospital procurement and pharmaceutical distribution at scale.

Key Milestones

2015: PharmEasy founded by five co-founders as an online pharmacy aggregator in Mumbai

Common questions about unlisted shares

How do I buy PharmEasy (API Holdings) unlisted shares here?
Raise an enquiry on any company with the quantity you want. Our desk sources the shares and comes back with a firm price and allocation. You accept the allocation, transfer the funds to the desk's published bank account, and once we verify payment the shares are transferred into your demat.
Who am I actually transacting with?
You transact with the desk, not with an anonymous counterparty. When you buy, you buy from the desk; when you sell, you sell to the desk. Shares always route through the desk's own demat account, so there's one accountable party for the whole trade.
How do I pay, and is there a payment gateway?

API Holdings Limited

How settlement works

Get price alerts for API Holdings Limited

Discuss PharmEasy (API Holdings)

Similar companies

Other ways to invest